Drug Approval | July 26, 2024
Sun Pharmaceutical receives USFDA approval for oral JAK inhibitor ‘Leqselvi’
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
10+ emerging markets, Japan & ANZ transition in final phase
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.
Subscribe To Our Newsletter & Stay Updated
